



News Release

Cougar Biotechnology to Present at the Leerink Swann Cancer Roundtable Conference

Los Angeles, CA, May 5, 2008 – Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at Leerink Swann’s Roundtable Conference, “Conquering Cancer with Novel Therapeutics,” on Friday, May 9, at 12:55 p.m. EDT at The Grand Hyatt Hotel in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar’s current clinical development programs.

Interested investors may access a live audio webcast by visiting the Investor Relations section of the Company’s Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar’s oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in a Phase III clinical trial in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

Contacts:

Cougar Biotechnology, Inc., +1-310-943-8040

Alan H. Auerbach, Chief Executive Officer and President

ahauerbach@cougarbiotechnology.com

Mariann Ohanesian, Director of Investor Relations

mohanesian@cougarbiotechnology.com

Russo Partners, LLC

David Schull, +1-212-845-4271

David.schull@russopartnersllc.com

Andreas Marathovouniotis, +1-212-845-4235

Andreas.marathis@russopartnersllc.com

###